Jueming Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a multi-route veterinary active pharmaceutical ingredient powder. The product designation acts as the model identifier; individual lots are traced by manufacturing order number and certificate of analysis rather than by a separate commercial item code. The material is qualified for seven dosage presentations, enabling a solid oral tablet campaign and a parenteral solution campaign to draw from the same controlled powder source when route-specific acceptance limits are met. Release documentation includes particle-size distribution, microbial enumeration, endotoxin, residual solvent, elemental impurity, and assay/related-substance data generated against the receiving product monograph and VICH GL18 residual solvent guidance. The grade is not a sterile API unless a specific lot is sterilized by a validated terminal process.

What Limits the Use of a Single API Powder Across Oral and Parenteral Veterinary Dosage Forms?

The controlling constraints are not assay or chemical identity, which remain route-independent, but particle-size distribution, microbial quality, and endotoxin burden. A powder that passes an oral premix specification may be unsuitable for injection because a D90 above 50 µm can obstruct 21 G needles and create local tissue irritation. A sterile-injection grade with a D50 below 20 µm may be over-milled for direct compression, producing cohesive agglomerates and poor die filling. The dual oral/parenteral specification therefore controls both upper and lower boundaries of particle size, along with a low endotoxin limit that would be unnecessary in a single-route oral powder.

Endotoxin control follows Ph. Eur. 2.6.14 and USP <85>. The oral block may legally release at a higher endotoxin level, but warehouses often standardize on the injection limit to avoid mis-selection of drums. Terminal sterilization of a non-sterile API is not a substitute for low bioburden; if a sterile lot is required, the user must perform validated dry-heat, filtration, or irradiation with a demonstrated sterility assurance level of 10⁻⁶. The API manufacturer supplies bioburden data, not a sterile claim, unless a sterile-grade campaign is specifically contracted.

Direct-compression tablet blends containing 70–80 wt% API and 15–20 wt% microcrystalline cellulose are screened through a 0.5 mm conical mill and mixed in a bin blender at 6–10 rpm for 15–25 min. This mixing window is narrow: below 15 min the blend may fail USP <905> uniformity, while above 45 min electrostatic charge increases and fine API particles segregate from coarse excipients. When the API D50 is below 25 µm, direct compression is usually replaced by wet granulation in a top-spray fluid bed with 5–10 wt% povidone binder at a product temperature of 28–32°C and an exhaust temperature of 50–55°C. Alternatively, twin-screw wet granulation on a 16 mm twin-screw extruder with an L/D ratio of 40:1, barrel temperature of 25–35°C, and screw speed of 200–400 rpm is suitable for continuous tablet-granule campaigns. The resulting granules have a D50 of 180–250 µm and a Carr index below 18, and the same granule fraction can be filled into hard capsules or sachets without a separate granulation campaign. High-speed rotary compression at 60 000 tablets/h generates frictional heat; 0.25–0.50 wt% sodium stearyl fumarate reduces sticking without the dissolution delay observed with 1.0 wt% magnesium stearate.

Solution and injection uses require separate compounding limits. The API is dissolved in water for injection at 20–25°C under low-light conditions; the solution is passed through a 0.22 µm polyvinylidene fluoride membrane filter and filled aseptically. For suspension injections, wet milling with 0.3 mm zirconium oxide beads reduces D90 to below 50 µm, but the milling time must be limited to avoid amorphization and particle-size rebound. The milled suspension is sterile-filtered only if the particle size is below the filter retention rating; otherwise it is prepared from a terminally sterilized intermediate or an irradiation-sterilized API powder. Filtration and milling parameters are not product-independent and are qualified on the actual formulation because excipients such as polysorbate 80 alter viscosity and particle wetting.

When Premix Carriers and Sterile-Solution Lines Require Different Documentation Sets

Feed premix manufacture introduces a segregation problem that solid-oral and parenteral lines do not share. The API must remain distributed in a carrier of calcium carbonate, dextrose, or rice hulls during pneumatic conveying and final feed dilution. A ribbon mixer running for 5–15 min at 10 sampling positions typically produces relative standard deviation below 5% when the API D50 is between 50 µm and 150 µm and the carrier particle size is 200–800 µm. If the API is finer, reverse addition and pre-coating of the carrier with 0.5–1.0 wt% vegetable oil reduce demixing but may alter release from the carrier-bound fraction. For injectable solutions, the same D50 is meaningless because the API is fully dissolved; the controlling data shift to subvisible particle counts per USP <788>, raw-material bioburden, and filter compatibility.

Differences from single-route veterinary powders are most visible in the release paperwork. A conventional oral powder may omit endotoxin testing, allow total aerobic microbial count at 10³ CFU/g, and may not report D90. The Jueming Powder Veterinary Grade API carries a dual specification block: oral parameters protect blend uniformity and premix carryover, while parenteral parameters protect syringeability, local tolerance, and pyrogen control. This avoids a commercial situation in which two separate API lots must be held for the same molecule, one for feed premix and one for injection. The product is not interchangeable with technical-grade powder, which may carry unspecified elemental impurities and lacks the VICH GL18 residual solvent statement required for a veterinary dossier.

The product differs from a commodity milled powder by its release matrix rather than by a single property. In tablet production, the absence of particle-size span data can appear as variable weight distribution, edge chipping, or punch filming; these are not machine failures but powder attribute failures. The multi-route certificate of analysis allows a production engineer to transfer the same lot from a solid oral line to a liquid parenteral line only after microbial and endotoxin re-evaluation; it does not remove the need for route-specific validation.

Stability, Moisture Uptake, and Warehouse Boundaries for Multi-Route API Lots

Unopened drums are released with a moisture specification that controls direct-compression performance. The powder is packaged in double low-density polyethylene liners inside a 25 kg high-density polyethylene drum; moisture-sensitive lots receive a nitrogen overlay at 99.0% purity. Storage at ≤ 25°C and ≤ 60% RH is assigned for the unopened container. A moisture threshold of 0.5% is the operational boundary for direct compression; above that value, flow index and tablet tensile strength decline unless the drum is reconditioned in a 40°C vacuum dryer for 8–12 h at ≤ 25 kPa. Karl Fischer titration per Ph. Eur. 2.5.12 or USP <921> is required after any excursion above 60% RH.

Dry premix stabilizers that shift pH outside a narrow range are incompatible. Blending with alkaline carriers above pH 8.0 accelerates hydrolytic degradation, and acidic carriers below pH 3.0 alter crystal habit after prolonged contact at 40°C and 75% RH. The powder should not be co-milled with strong oxidising agents; residual peroxide above 10 ppm in the blend is associated with related-substance increases during open-chamber stability at 30°C/65% RH. These boundaries are operational limits, not regulatory release limits, and must be re-confirmed for the specific formulation.

Batch-to-batch variance is controlled by in-process particle-size and moisture trending. Near-infrared probes installed in the blender monitor homogeneity in the spectral region 4000–8000 cm⁻¹, avoiding water bands that interfere in the 3000–3700 cm⁻¹ region. For a 25 kg drum campaign, sublots are taken from top, middle, and bottom after drying; the acceptable assay relative standard deviation across sublots is ≤ 2.0% and the moisture difference is ≤ 0.1%. If these limits are exceeded, the campaign is re-dried and re-sampled, not blended forward without a root-cause investigation.

For oral solutions and drinking-water powders, the powder is wetted with glycerin or propylene glycol before dilution in aqueous buffer to avoid floating and foaming. Headspace oxygen in multi-dose drinking-water tanks is reduced with nitrogen at 99.5% purity; solution stability is evaluated in polypropylene tanks because leachates from some polyethylene terephthalate containers alter pH after 72 h. For granules and sachets, extrusion-spheronization with 0.6–1.2 mm dies requires a wet mass with loss on drying of 12–18%, but wet mass dwell time is limited to ≤ 30 min to avoid hydrate formation. Spheroids are dried at 60°C for 20–40 min to a final moisture content below 0.5%.

Final feed dilution uses a 1:10 step-down pre-blend before a 1:1000 final feed addition. The carrier should have a peroxide value below 5 meq/kg to avoid oxidation during a 90-day shelf life. Recovery after storage in a vertical feed silo at 30°C and 65% RH for 30 days should remain within 95–105% of label claim. Pellet conditioning at 80–85°C for 20–30 s may degrade heat-sensitive molecules, so stability in actual pelleted feed must be confirmed by the feed mill rather than assumed from powder stability data.

Pilot-scale lots of 1 kg are supplied in polyester/aluminum foil/linear low-density polyethylene laminate pouches with desiccant when the moisture specification is below 0.2%. Commercial lots of 25 kg use double polyethylene liners and a fiberboard drum; the desiccant mass is calculated from the water vapor transmission rate of the primary liner, not added arbitrarily. Sublot subdivision from a larger blending campaign is performed only after pass-through of the multi-route release panel; sublot assay variance is reported in the certificate of analysis.

The grade is manufactured under a quality system aligned with VICH GL1 and EU GMP Part II for active substances used in veterinary medicinal products. The documentation does not automatically satisfy human ICH Q3D elemental impurity or human parenteral monograph requirements because target animal body weight, lifetime exposure, and residue depletion assumptions differ. The powder is not sold as sterile, and a sterile claim requires a separate validated campaign or terminal sterilization step. The user must verify that the selected lot meets the exact registered specification in the country of submission.